Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (KNSA) is a clinical and commercial-stage biopharmaceutical company pioneering immune-modulating therapies for autoimmune and cardiovascular diseases. This dedicated news hub provides investors, researchers, and healthcare professionals with timely updates on corporate developments and scientific advancements.
Access the most comprehensive collection of Kiniksa news including regulatory milestones, clinical trial results, and strategic partnerships. Our curated feed delivers essential updates on ARCALYST commercialization progress, abiprubart development phases, and pipeline expansion efforts – all critical for informed decision-making in biopharma investing.
Key content categories cover FDA submissions, research collaborations, financial performance, and therapy access initiatives. The centralized format ensures efficient tracking of Kiniksa's progress in addressing complex inflammatory conditions through targeted immune modulation.
Bookmark this page for streamlined monitoring of KNSA's evolving position in autoimmune therapeutics. Verify information accuracy through direct links to official company communications and peer-reviewed clinical data sources.
Kiniksa Pharmaceuticals has partnered with GRAMMY Award-winning country star Carly Pearce for their Life DisRPted™ campaign, focusing on raising awareness for recurrent pericarditis. Pearce, who was diagnosed with the condition in 2024 after experiencing multiple flares over four years, joins NHL Hall-of-Famer Henrik Lundqvist in the campaign.
The initiative aims to educate patients and caregivers about this chronic autoinflammatory heart disease, which is often underdiagnosed. Through a video titled "The Power of Knowing" available on LifeDisRPted.com, Pearce shares her personal journey and emphasizes the importance of self-advocacy.
Recurrent pericarditis symptoms include:
- Chest pain
- Tiredness
- Shortness of breath
- Reduced exercise capacity
The campaign provides resources including a Doctor Discussion Guide to help patients better communicate with healthcare providers.
Kiniksa Pharmaceuticals reported strong Q1 2025 financial results, with ARCALYST generating net product revenue of $137.8 million, marking a 75% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $590-605 million from previous $560-580 million.
Key highlights:
- Over 3,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis
- Average treatment duration increased to 30 months from 27 months in Q4 2024
- Total Q1 2025 revenue: $137.8 million
- Net income: $8.5 million, compared to $17.7 million loss in Q1 2024
- Cash position: $268.3 million with no debt
The company plans to initiate a Phase 2/3 trial for KPL-387 in mid-2025, with Phase 2 data expected in 2H 2026. KPL-387 aims to offer monthly subcutaneous dosing for recurrent pericarditis. Kiniksa expects to maintain positive annual cash flow and continues monitoring potential tariff implications on pharmaceuticals.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has scheduled its first quarter 2025 financial results conference call and webcast for Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time. The company will discuss Q1 2025 financial performance and recent portfolio developments.
The event will be accessible through a live webcast in the Investors & Media section of www.kiniksa.com. Interested participants can register for telephone access, after which they will receive confirmation details including dial-in information and unique access credentials. A replay will be available on the company website within 48 hours after the event.
Kiniksa Pharmaceuticals reported strong ARCALYST sales growth of 79% year-over-year, reaching $417.0 million for full year 2024 and $122.5 million for Q4 2024. The company projects 2025 ARCALYST net product revenue between $560-$580 million.
The company is prioritizing cardiovascular indications in its development pipeline. Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 for recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026. KPL-387 offers potential monthly subcutaneous dosing. Additionally, KPL-1161 is advancing toward clinical development with a target of quarterly subcutaneous dosing.
Kiniksa will discontinue development of abiprubart in Sjögren's Disease and has terminated its exclusive license agreement for mavrilimumab with MedImmune. The company reported a net loss of $8.9 million for Q4 2024 and $43.2 million for full year 2024, but expects its current operating plan to remain cash flow positive annually.
Kiniksa Pharmaceuticals announced the development of KPL-387 for recurrent pericarditis, with plans to initiate a Phase 2/3 clinical trial in mid-2025. Phase 1 single ascending dose data supports potential monthly dosing with a subcutaneous injection in liquid formulation.
The company is prioritizing cardiovascular indications in its development strategy while discontinuing abiprubart development in Sjögren's Disease and terminating its mavrilimumab license agreement with MedImmune.
Since launching ARCALYST in 2021 for recurrent pericarditis, Kiniksa has generated over $800 million in product revenue and achieved positive annual cash flow. The company plans to further increase ARCALYST's market penetration while developing KPL-387 to expand treatment options.
Additionally, Kiniksa is advancing KPL-1161, another monoclonal antibody targeting IL-1R1, with a target profile of quarterly subcutaneous dosing.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website. Interested participants can register for telephone access, and a replay will be available on the website within 48 hours after the event.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported preliminary unaudited ARCALYST net product revenue of $416.4 million for 2024, showing approximately 79% year-over-year growth. The company provided 2025 revenue guidance of $560-580 million.
Q4 2024 ARCALYST revenue reached $121.9 million. The drug's uptake in recurrent pericarditis continues to grow, with approximately 13% of the 14,000 multiple-recurrence target population actively on therapy. More than 2,850 prescribers have written ARCALYST prescriptions, with patients maintaining an average treatment duration of 27 months.
The company reported $243.6 million in cash, cash equivalents, and short-term investments as of December 31, 2024, and expects to remain cash flow positive annually.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Investors and interested parties can access a live webcast of the presentation through the Investors section of Kiniksa's website at www.kiniksa.com. Additionally, a replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 7th Annual Evercore ISI HealthCONx Conference. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 9:35 a.m. Eastern Time.
The presentation will be accessible via live webcast through the Investors section of Kiniksa's website at www.kiniksa.com. A replay of the presentation will be made available on the company's website within approximately 48 hours following the event.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has announced its upcoming participation in the 2024 Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT (7:00 a.m. ET).
Interested parties can access a live webcast of the presentation through the Investors section of Kiniksa's website at www.kiniksa.com. A replay will be made available on the company's website within 48 hours after the event.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
